The tissue availability of active glucocorticoids (cortisol in humans) depends on their rate of synthesis from cholesterol, downstream metabolism, excretion and interconversion. The latter is mediated by the 11β-hydroxysteroid dehydrogenases (11βHSDs). In this review, we summarize the features of the two isoenzymes, 11βHSD1 and 11βHSD2, and current available experimental data related to 11βHSDs, which are relevant in the context of synovial cells in rheumatoid arthritis (RA). We conclude that due to complex feedback mechanisms inherent to the hypothalamic-pituitary-adrenal axis, currently available transgenic animal models cannot display the full potential otherwise inherent to the techniques. Studies with tissue explants, mixed synovial cell preparations, cell lines derived from synovial cells, and related primary cells or established cell lines indicate that there are relatively clear differences between the two isoenzymes. 11βHSD1 is expressed primarily in fibroblasts and osteoblasts, and may be responsible for fibroblast survival and aid in the resolution of inflammation, but it is also involved in bone damage. 11βHSD2 is expressed primarily in macrophages and lymphocytes, and may be responsible for their survival, suggesting that it is critical in chronic inflammation. The situation in synovial tissue would allow 11βHSD2-expressing cells to tap the energy resources of 11βHSD1-expressing cells. The overall properties of this local glucocorticoid interconversion system might limit therapeutic use of glucocorticoids in RA.

1.
Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949;24:181-197.
2.
Bailey E, Greaves MS, Murphy D, West HF: Corticosteroid metabolism and rheumatoid arthritis. Ann Rheum Dis 1966;25:516-524.
3.
Murphy D, West HF: Catabolism and interconversion of cortisol and cortisone in human synovial tissue in vitro. Ann Rheum Dis 1969;28:637-643.
4.
Hillier SG: Diamonds are forever: the cortisone legacy. J Endocrinol 2007;195:1-6.
5.
Miller WL: Steroidogenic enzymes. Endocr Dev 2008;13:1-18.
6.
Gathercole LL, Lavery GG, Morgan SA, Cooper MS, Sinclair AJ, Tomlinson JW, Stewart PM: 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev 2013;34:525-555.
7.
Chapman K, Holmes M, Seckl J: 11β-Hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev 2013;93:1139-1206.
8.
Seckl JR, Walker BR: 11β-Hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 2004;15:418-424.
9.
Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM: 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-866.
10.
Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS: Cloning and tissue distribution of the human 11 β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994;105:R11-R17.
11.
White PC, Agarwal AK, Nunez BS, Giacchetti G, Mantero F, Stewart PM: Genotype-phenotype correlations of mutations and polymorphisms in HSD11B2, the gene encoding the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Endocr Res 2000;26:771-780.
12.
Morris DJ, Latif SA, Hardy MP, Brem AS: Endogenous inhibitors (GALFs) of 11β-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. J Steroid Biochem Mol Biol 2007;104:161-168.
13.
Balazs Z, Nashev LG, Chandsawangbhuwana C, Baker ME, Odermatt A: Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11β-hydroxysteroid dehydrogenase 1. Mol Cell Endocrinol 2009;301:117-122.
14.
Mitic T, Shave S, Semjonous N, McNae I, Cobice DF, Lavery GG, Webster SP, Hadoke PW, Walker BR, Andrew R: 11β-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo. Biochem Pharmacol 2013;86:146-153.
15.
Odermatt A, Kratschmar DV: Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview. Mol Cell Endocrinol 2012;350:168-186.
16.
Condon J, Gosden C, Gardener D, Nickson P, Hewison M, Howie AJ, Stewart PM: Expression of type 2 11β-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. J Clin Endocrinol Metab 1998;83:4490-4497.
17.
Rabbitt EH, Ayuk J, Boelaert K, Sheppard MC, Hewison M, Stewart PM, Gittoes NJ: Abnormal expression of 11β-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene 2003;22:1663-1667.
18.
Holmes MC, Kotelevtsev Y, Mullins JJ, Seckl JR: Phenotypic analysis of mice bearing targeted deletions of 11β-hydroxysteroid dehydrogenases 1 and 2 genes. Mol Cell Endocrinol 2001;171:15-20.
19.
Coutinho AE, Gray M, Brownstein DG, Salter DM, Sawatzky DA, Clay S, Gilmour JS, Seckl JR, Savill JS, Chapman KE: 11β-Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology 2012;153:234-240.
20.
Ergang P, Leden P, Vagnerova K, Klusonova P, Miksik I, Jurcovicova J, Kment M, Pacha J: Local metabolism of glucocorticoids and its role in rat adjuvant arthritis. Mol Cell Endocrinol 2010;323:155-160.
21.
Cooper MS, Stewart PM: 11β-Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009;94:4645-4654.
22.
Schmidt M, Naumann H, Weidler C, Schellenberg M, Anders S, Straub RH: Inflammation and sex hormone metabolism. Ann NY Acad Sci 2006;1069:236-246.
23.
Buttgereit F, Zhou H, Kalak R, Gaber T, Spies CM, Huscher D, Straub RH, Modzelewski J, Dunstan CR, Seibel MJ: Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum 2009;60:1998-2007.
24.
Edwards C: Sixty years after Hench: corticosteroids and chronic inflammatory disease. J Clin Endocrinol Metab 2012;97:1443-1451.
25.
Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM: Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001;16:1037-1044.
26.
Schmidt M, Weidler C, Naumann H, Anders S, Scholmerich J, Straub RH: Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? Arthritis Rheum 2005;52:1711-1720.
27.
Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A: 11β-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 2001;167:30-35.
28.
Antoniv TT, Ivashkiv LB: Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum 2006;54:2711-2721.
29.
Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL, Rabbitt EH, Stewart PM, Buckley CD, Hewison M: Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther 2006;8:R108.
30.
Kaur K, Hardy R, Ahasan MM, Eijken M, van Leeuwen JP, Filer A, Thomas AM, Raza K, Buckley CD, Stewart PM, Rabbitt EH, Hewison M, Cooper MS: Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation-associated bone loss. Ann Rheum Dis 2010;69:1185-1190.
31.
Ahasan MM, Hardy R, Jones C, Kaur K, Nanus D, Juarez M, Morgan SA, Hassan-Smith Z, Benezech C, Caamano JH, Hewison M, Lavery G, Rabbitt EH, Clark AR, Filer A, Buckley CD, Raza K, Stewart PM, Cooper MS: Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells. Arthritis Rheum 2012;64:2404-2413.
32.
Hardy R, Juarez M, Naylor A, Tu J, Rabbitt EH, Filer A, Stewart PM, Buckley CD, Raza K, Cooper MS: Synovial DKK1 expression is regulated by local glucocorticoid metabolism in inflammatory arthritis. Arthritis Res Ther 2012;14:R226.
33.
Olsen N, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, Aune TM: A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis 2004;63:1387-1392.
34.
Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, Gittoes NJ, Buckley CD, Raza K, Cooper MS: Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008;67:1204-1210.
35.
Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines GK, Ling S, Chinnaiyan AM, Holoshitz J: Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 2006;54:2047-2060.
36.
Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR: Local amplification of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response. Ann NY Acad Sci 2006;1088:265-273.
37.
Viegas LR, Hoijman E, Beato M, Pecci A: Mechanisms involved in tissue-specific apopotosis regulated by glucocorticoids. J Steroid Biochem Mol Biol 2008;109:273-278.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.